Skip the main content if you do not want to read it as the next section.
Skip the location trail if you do not want to read it as the next section.
Location trail
HEALTH PROFESSIONALS > TREATMENT GUIDELINES > SPECIFIC CANCERS > LYMPHOMAUK treatment guidelines - Lymphomas
- Guideline on the use of Colony Stimulating Factors in Haematological Malignancies - BCSH - 2003
- Joint British Association of Dermatologists and UK cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas - BAD, 2003
- Guidance on the use of rituximab for recurrent or refractory Stage III or IV follicular non-Hodgkin lymphoma, 2002
- Guidelines on the provision of facilities for the care of adult patients with haematological malignancies. (including leukaemia, lymphoma and severe bone marrow failure.) – BCSH - 1995
Guideline on the use of Colony Stimulating Factors in Haematological Malignancies - BCSH - 2003
Produced by: The British Committee for Standards in Haematology (BCSH) is a sub-committee of the British Society for Haematology (BSH).
Purpose: To provide haematologists with up to date advice on the diagnosis and treatment of haematological disease by the production of evidence based guidelines.
Can be obtained from: British Journal of Haematology 2003; v123(1), p22-33 or British Society for Haematology, 100 White Lion Street, London N1 9PF. Tel: 020 8643 7305
Joint British Association of Dermatologists and UK cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas - BAD, 2003
Produced by: British Association of Dermatologists
Purpose: To present evidence-based guidance for treatment and a brief overview of epidemiological aspects, diagnosis and investigation.
Can be obtained from: British Journal of Dermatology 149 2003, p1095-1107 or The British Association of Dermatologists, 19 Fitzroy Square, London W1P 5HQ. Tel: 020 7383 0266
Guidance on the use of rituximab for recurrent or refractory Stage III or IV follicular non-Hodgkin lymphoma, 2002
Produced by: NICE, National Institute for Clinical Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA, March 2002, Technology Appraisal Guidance No.37
Purpose: Guidance on the use of rituximab for follicular non-Hodgkin lymphoma.
Can be obtained from: Copies of this guidance can be obtained from the NHS Response Line by telephoning 0870 1555 455 and quoting ref: N0078. A patient version of this document can be obtained by quoting ref: N0080. A bi-lingual patient leaflet is also available, ref: N0081
Guidelines on the provision of facilities for the care of adult patients with haematological malignancies. (including leukaemia, lymphoma and severe bone marrow failure.) – BCSH - 1995
Produced by: The British Committee for Standards in Haematology (BCSH) is a sub-committee of the British Society for Haematology (BSH).
Purpose: To provide haematologists with up to date advice on the diagnosis and treatment of haematological disease by the production of evidence based guidelines.
Can be obtained from: Clinical and Laboratory Haematology 1995; v17, p3-10 or The British Society for Haematology, 100 White Lion Street, London N1 9PF Tel: +44 (0) 20 8643 7305
Content last reviewed: 01 November 2003
Page last modified: 14 January 2009
Page last modified: 14 January 2009